Replies to post #197409 on Biotech Values

[DewDiligence]

STEM -11% on 25% workforce reduction and termination of AMD program (buried in PR on “strategic realignment”):

http://finance.yahoo.com/news/stemcells-inc-announces-strategic-realignment-130500133.html

“The decision to prioritize our spinal cord injury program required some difficult choices, including the suspension of the Company’s Phase II Radiant Study in geographic atrophy of age-related macular degeneration (GA-AMD) while we seek a partner to fund continued development in retinal disorders,” said StemCells’ CEO Martin McGlynn.